FORCE Family Office

We're hosting investor webinars with two great companies this week. Sign up to join us and learn about these new technologies that have the potential to shape the future in healthcare and clean energy. Tuesday, October 8, 12:00 PM ET BioVie: BioTech Earns $12.6M Grant From The Department of Defense https://lnkd.in/gg53B-XJ Thursday, October 10, 12:00 PM ET The Metals Company: Sustainable Mineral Collection from the Deep Sea https://lnkd.in/gHNGkvfD

Our friends at InPipe Energy are sponsoring a FREE Webinar Wednesday, October 1 that you'll want to check out if you're interested in clean energy solutions to climate change: Net Zero 2035: The Challenge Starts Now As climate change accelerates at a rapid pace, there is an urgent need to direct resources to take action, and attention to decarbonization. We do not have the luxury of time. This webinar will focus on identifying and prioritizing the barriers and challenges we will need to achieve industry decarbonization by 2050. #climatechange #cleanenergy #innovation #technology #cleantech #webinar https://lnkd.in/gYMdUpp8

Where are family offices putting their money and what are the biggest challenges they're facing? Here are our 5 key take-aways from the 2024 CITI Private Bank Global Family Office Survey... 1. Cash Is Moving Off The Sidelines: They are moving their assets from cash to fixed income as well as public and private equities to take advantage of higher interest rates and strong market performance. 2. New Kids On The Block: 50% of the 337 respondents are first generation Family Offices who are trying to get their arms around governance, family unity, and continuity. 3. The Running Of The Bulls: Hopes are high for their investments, with 97% expecting asset growth and 34% looking for returns of 10% or more. 4. Uncertainty Abounds: Real Estate remains an enigma with 37% bullish on the asset, 45% neutral, and 18% bearish. 5. Risky Business: Cybersecurity, geopolitics, and family dynamics are the three threats that keep the leaders of Family Offices up at night. There is a lot more good information if you dig through the 150-page report which you can download here. Let us know your thoughts about what you think are the biggest issues and opportunities facing Family Offices today.

Moleculera Biosciences is a precision medicine company focused on uncovering the immune-mediated roots of and guiding the treatment for a wide range of chronic disorders.Immune dysfunction and inflammation are the root cause of some of the hardest to diagnose and most devastating diseases. In fact, up to 85% of psychiatric disorders including ADHD, OCD, Schizophrenia, and Autism have immune-mediated causes. That’s why many patients don’t respond to traditional psychotropic medications and treatments. In response, Moleculera created the Autoimmune Brain Panel, a series of five blood tests that identify the infections that lead to neuropsychiatric disorders. Clinically validated in more than 15,000 patients, the impact of Moleculera’s breakthrough has been both wide ranging and immediate. The Autoimmune Brain Panel is in market and been ordered by more than 2,500 doctors in 50 countries, generating revenue for Moleculera. has built the world’s largest biorepository and bioinformatics database of clinically annotated specimens from patients suffering from immune-mediated disorders. This is fueling the discovery and development of novel biomarkers and potential therapeutic targets. Using their exclusive data, the company has several additional testing panels in the pipeline targeting cardiovascular, Long-COVID, and neurodegenerative disorders. Please sign up to join this webinar with Moleculera Biosciences President and CEO, Craig Shimasaki, to learn how their innovative technology has the potential to improve millions of lives.

Sensorium Therapeutics, an innovative biotech company that has developed a state-of-the-art AI product engine to discover and develop drugs for central nervous system (CNS) diseases.Sensorium has built a database of 300,000 natural compounds and uses a proprietary AI algorithm to determine relationships between their chemical structures and physiochemical properties with historical records of human use. This allows the company to develop new medicines on relatively short timelines with novel pharmacology and a high probability of success in the clinic. Sensorium’s platform has already discovered and is rapidly advancing three first-in-class programs, which address large markets with high unmet needs including Social Anxiety Disorder – the third most common psychiatric disease whose current treatment options have significant shortcomings. In addition, Sensorium Therapeutics has also identified other compounds with human data in Alzheimer’s, epilepsy. obesity, diabetes, depression, and non-opioid pain treatment. Register now to join our webinar with Sensorium CEO, Alexandra (Sandra) Glucksmann, to hear how the company’s AI-powered drug development program has the potential to impact millions of lives.

GruEnergy is a private company that is leveraging a breakthrough in material science to accelerate the world’s transition from fossil fuels to carbon-free power. The company has a patented process that produces high performing silicon-based anode materials that will disrupt the electric vehicle battery market. Batteries made with their silicon: - Cost 50% less than current silicon anode materials - Charge in 1/3 the time - Have more capacity - Have a significantly smaller carbon footprint GruEnergy has been working with leading automakers and battery manufacturers, including BMW, to develop their technology and are in the process of building a pilot plant to begin commercialization of their products. Bloomberg NEF estimates that by 2030 we will need 54,000 metric tons of silicon to produce the high performance batteries needed for automotive, aviation, consumer products, portable energy systems and other applications. This is creating a huge opportunity for GruEnergy. Join our webinar with GruEnergy CEO, Song Han, to learn more about the opportunity created by their strategy to capture a large market share via patented, disruptive, low cost production methods. Hosted by Steven Saltzstein, CEO, Force Family Office

Sigyn Therapeutics (OTCQB: SIGY) is creating therapeutic solutions that overcome current limitations in healthcare. One of the reasons cancer therapies like checkpoint inhibitors and chemotherapy have such a low success rate is that tumor derived exosomes and drug decoys can prevent therapeutics from reaching their targets. Sigyn’s ImmunePrep platform enhances the activity of antibody-based immunotherapies while ChemoPrep improves the delivery of cancer chemotherapies, and ChemoPure reduces the post-treatment toxicity of chemotherapy.In addition, Sigyn is developing a modular feasibility study for Sigyn Therapy to help extend the lives of end-stage renal disease patients. Join our webinar with Sigyn co-founder and CEO, Jim Joyce, to hear how Sigyn’s patented devices improve the performance of drugs that treat cancer. Hosted by Force Family Office CEO, Steven Saltzstein

It comes as a surprise to some when they learn that the world’s 1.5 billion beef cattle produce as much methane as the oil and gas industry. That’s up to 30% of the world’s methane, a greenhouse gas 28 times more harmful than CO2. Yet, it’s possible to eliminate 90% of the problem without reducing the amount of meat we eat. CH4Global has created a natural supplement that when added to a cow’s feed, prevents methane from being produced during digestion. Methane Tamer is produced from dried, whole Asparagopsis, aka red seaweed. When used as a feed additive in very small amounts, it has been shown to significantly reduce enteric methane emissions in beef cattle, dairy cows, and sheep, with no adverse effects to livestock, their products, or the environment. The only effect is a dramatic reduction in greenhouse gases. Working with the largest feed producers and consumer-facing food companies on the planet, CH4Global is on a mission to create methane-free herds around the world. The company has scaled process, so it is profitable, and most importantly, provides a net positive return on their investment to the farmer, the lifeline for the global food industry. Methane Tamer is good for people and the planet. The company is vertically integrated, controlling both the growing of the raw material and production facilities to create their patented supplements. Join this webinar with CH4 Global CEO, Steve Meller, to hear about the company’s vertically integrated business model and their 3 large scale pilot plants that are producing supplements for use in Australia, New Zealand, South Korea and other countries.

While e-bikes have been a boon for the bicycle industry worldwide, that’s especially true in Europe where sales are expected to surpass all car sales by 2030. Traditional bicycle companies are fighting each other with undifferentiated products at ever narrowing margins. Cowboy, a new bicycle company based in Belgium, is taking a different path. Taking design, engineering, and technology cues from companies like Apple, Tesla, and Peloton, Cowboy is building a bike that is beautiful, easy to ride, and connected. Starting with a clean sheet of paper, Cowboy offers a fresh perspective on bicycle design. At the core, their bikes are driven by a proprietary motor system controlled by bespoke software – Cowboy AdaptivePower – that provides automatic assistance, eliminating the need for manual gears and ride modes. Their sustainable differentiator, however, is their connected App which creates a powerful rider community. As Oscar Salazar, Co-Founder of Uber said, “Cowboy’s true customer advantage is its rich digital ecosystem.” It provides everything from ride stats and power analysis to rider alerts, crash and theft detection, and gamification strategies like rider groups, leaderboards, and social sharing. With over 65 thousand bikes sold to date, Cowboy is on track to generate €35M revenue in 2024. Register now to join this webinar to hear from Founder and CEO, Adrien Roose, and CFO, Mark Vincent, to hear how Cowboy’s product, technology, and distribution strategies will help the company become cash flow positive and profitable in 2025. Hosted by Steven Saltzstein, CEO of Force Family Office

Angiex Inc. is on a path to making cancer a non-lethal disease. Their lead product, AGX101, has the potential to transform cancer treatment.AGX101 is founded on a special biology, a protein called TM4SF1 that is necessary for the growth of tumor blood vessels and for the invasion or metastasis of tumor cells. AGX101 is a novel Antibody-Drug Conjugate (ADC) that targets cancer lethality through three distinct mechanisms of action: - Attacking Tumor Blood Vessels: By destroying the blood vessels that supply tumors without harming normal blood vessels, AGX101 shrinks tumors to minimal size. - Activating Anti-Tumor Immunity: AGX101 enhances the body’s immune response against cancer, increasing the likelihood of complete responses to therapy. - Killing Invasive and Metastatic Tumor Cells: Killing these cells may eliminate cancer’s ability to invade or metastasize – processes thought to account for 90% of cancer deaths. AGX101 has the largest preclinical therapeutic margin ever seen in an oncology drug, indicating potential for unprecedented safety. It is a true “magic bullet,” delivering a ten-fold higher fraction of injected drug to the tumor than other ADCs. Phase 1 clinical trials are currently underway, with encouraging early results. Join our webinar with Angiex Founder and CEO, Paul Jaminet, to hear more about the company’s vision that no one should die of cancer and how it has the practical means to achieve that vision. Hosted by Steven Saltzstein, CEO, Force Family Office